Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of November 2023, with a report date of November 27, 2023. The filing details significant strategic transactions involving the acquisition of rights to the compound tolimidone, a selective activator of the enzyme lyn kinase intended to amplify insulin signaling. The company is currently conducting a registered offering (Form F-1) to facilitate these transactions.
Key Financial Metrics and Transaction Values
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it focuses on specific transactional agreements. Key financial values disclosed include:
- Initial Cash Consideration to Adhera: $0.3 million.
- Initial Equity Consideration to Adhera Noteholders: $2.0 million in American Depositary Shares (ADS).
- Contingent Cash Consideration: Additional $0.4 million payable to Adhera if Secured Noteholders subscribe for at least $4.0 million in the Offering.
- Contingent Equity Consideration: Additional $3.0 million in ADS to Secured Noteholders upon the $4.0 million subscription threshold.
- Milestone Payments: Aggregate $4.0 million in ADS payable upon completion of a positive Phase II clinical study and first commercial sale.
- Upfront Equity to Melior: 9.9% of the fully-diluted number of ADS (50% of which is issued to Bukwang).
- Advance Payment: $60,000 advanced to Adhera, creditable against the initial cash consideration or repayable if the closing does not occur by March 31, 2024.
- Royalties: Single-digit tiered royalties on net sales payable to Melior (with 50% passed to Bukwang).
Material Changes and Agreements
The filing reports the execution of three primary agreements on November 22, 2023:
- Assignment and Exchange Agreement (A&E): Adhera Therapeutics, Inc. assigned all rights to tolimidone to Biodexa. In exchange, Adhera's Secured Noteholders will receive cash and ADS, and their secured notes will be cancelled upon closing.
- Tolimidone License Agreement: Biodexa obtained an exclusive, worldwide license from Melior Pharmaceuticals I, Inc. to develop and commercialize tolimidone. This requires the issuance of 9.9% of fully-diluted ADS to Melior (and Bukwang) and payment of future royalties.
- Bukwang Amendment: Melior and Bukwang Pharmaceutical Co. Ltd. agreed to terminate Bukwang's existing license upon Biodexa securing a minimum of $4.0 million in new equity financing by September 30, 2024. Upon termination, Bukwang will transfer rights to Melior and receive 50% of royalties and equity consideration.
Additionally, the company announced the resignation of its depositary, The Bank of New York Mellon, and is in discussions to appoint a successor.
Guidance, Outlook, and Risks
Outlook and Conditions: The closing of the A&E Agreement and the effectiveness of the Tolimidone License are contingent upon the closing of the Company's registered Offering and the filing of a resale registration statement. The company must secure a minimum of $4.0 million in new equity financing within 90 days of the license effective date to avoid termination by Melior.
Lock-Up and Resale: Shareholders receiving ADS under these agreements are subject to lock-up periods (90 days post-resale effectiveness or 180 days post-closing). Limited "leak-out" provisions allow sales of up to 30% of daily trading volume (or 5.5% for Melior/Bukwang) unless the share price exceeds 150% of the offering price.
Risks: The filing includes standard forward-looking statement disclaimers. Key risks include the failure to satisfy closing conditions, market conditions affecting the Offering, and the uncertainty of clinical trial outcomes for tolimidone.
Investor Verification Checklist
- Verify the status and closing date of the Company's registered Offering (Form F-1) to confirm if the $4.0 million financing threshold is met.
- Confirm the appointment of a successor depositary to replace The Bank of New York Mellon.
- Monitor the filing of the Resale Registration Statement for the ADS issued to Adhera Noteholders, Melior, and Bukwang.
- Review the full text of Exhibits 10.1 through 10.6 for specific terms regarding milestone payments and royalty calculations.
- Assess the timeline for the Bukwang License termination, which is tied to the September 30, 2024 financing deadline.